Skip to main content
SpringerLink
Log in

Diagnosis and treatment of endometrial carcinoma

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Approximately 6000 endometrial cancer death occurs annually worldwide, predominantly noticed in postmenopausal women. The current diagnostic and therapeutic research trials for endometrial carcinoma are giving new clues to select best postoperative adjuvant treatment especially in high risk disease. Transvaginal ultrasound and hysteroscopy endometrial biopsies are tending to replace the dilation and curettage in establishing a diagnosis. The standard primary treatment of endometrial carcinoma is surgery but to select best adjuvant therapy, the risk of disease recurrence is determined by certain pathological factors and also by surgical stage. The most commonly used adjuvant therapy is radiation therapy but satisfactory results have not been noticed in high-risk endometrial carcinoma. On the basis of review of current research guidelines it is indicated that hormonal or chemotherapeutic agents must be added with radiation therapy to improve prognosis and efficacy in endometrial carcinoma after surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Creasman WT. Endometrial carcinoma. Accessed 6th August 2007, http://www.emedicine.com/med/topic674.htm.

  2. Rose PG. Endometrial carcinoma. N Engl J Med, 1996, 335: 640–649.

    Article  PubMed  CAS  Google Scholar 

  3. Canavan PT, Doshi RN. Endometrial cancer. Am Acad Fam Physicians, 1999, 59: 3077.

    Google Scholar 

  4. Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Cancer, 1997, 79: 320–326.

    Article  PubMed  CAS  Google Scholar 

  5. Gardner GJ, Montz FJ. Cancer of the uterine corpus. China: Lippencott Williams & Wilkins Inc, 2003. 476–477.

    Google Scholar 

  6. Kopljar M. Endometrial cancer for layman & student. Accessed 23rd April 2007, http://www.cancerlinks.com/endometrial/index.html.

  7. Gibb RK, Katsanis WA. Uterine cancer. USA: McGraw-Hill companies, 2001. 1281–1290.

    Google Scholar 

  8. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by gynecologic oncology group. J Clin Oncol, 1999, 17: 1736–1743.

    PubMed  CAS  Google Scholar 

  9. Khan RL. Tumors of uterus, tubes & ligaments. India: CBS publishers & Distributors, 1996. 213–215.

    Google Scholar 

  10. Sakala EP. Menopause. USA: Lippencott Williams & Wilkins, 2000. 324–326.

    Google Scholar 

  11. Burke TW, Morris M. Surgery for malignant tumors of the uterine corpus. China: Health Science Asia, Elsevier Science, 2002. 535–538.

    Google Scholar 

  12. Jones HW, Jones GS. Endometrial carcinoma. USA: William & Wilkins Company, 1981. 414.

    Google Scholar 

  13. Gadducci A, Cosio S, Genazzani AR. Treatment planning in endometrial cancer. Cancer Ther, 2003, 11: 373–391.

    Google Scholar 

  14. Tangjitgamol S, Manusirivithaya S, Lertbutsayanukul C. Adjuvant therapy for early-stage endometrial cancer: a review. Int J Gynecol Cancer, 2007,17: 949–956.

    Article  PubMed  CAS  Google Scholar 

  15. Minckwitz GV, Loibl S, Brunnert K, et al. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer — a multicenter, open, controlled, prospectively randomized trial. Eur J Cancer, 2002, 38: 2265–2271.

    Article  Google Scholar 

  16. COSA-NZ-UK Endometrial Cancer Study Groups. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. Int J Gynecol Cancer, 1998, 8: 387–391.

    Article  Google Scholar 

  17. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs. radiotherapy in high risk endometrial carcinoma, results of a randomized trial. Br J Cancer, 2006, 95: 226–271.

    Article  Google Scholar 

  18. Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitexal chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol, 2006, 103: 155–159.

    Article  PubMed  CAS  Google Scholar 

  19. Nordic Society for Gynecologic Oncology. Phase III randomized study of adjuvant radiotherapy with or without chemotherapy in patients with high-risk endometrial carcinoma. Accessed 8th August 2007, http://www.clinicaltrial.gov/ct/show/NCT00006027.

  20. Endometrial cancer (PQD): treatment health professional version. National Cancer Institute. Accessed 1st May 2007, http://www.cancer.gov/cancertopic/pdq/treatment/endometrial/health professional.

  21. Hanlan KO. Endometrial carcinoma. Accessed 9th August 2007, http://www.ohanlan.com/PDFs/hyperplasia.pdf.

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, 430060, China

    Rumana Jafarey & Wei Zhang

Authors
  1. Rumana Jafarey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rumana Jafarey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jafarey, R., Zhang, W. Diagnosis and treatment of endometrial carcinoma. Chin. -Ger. J. Clin. Oncol. 7, 170–175 (2008). https://doi.org/10.1007/s10330-007-0178-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-007-0178-1

Key words

Search

Navigation